Navigation Links
Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms
Date:11/9/2009

al of 58 percent said they plan to deploy within 12 months, resulting in the new server adoption rate projected at almost twice the new workstation adoption rate in the enterprise.
  • According to InformationWeek Analytics Windows 7 survey, two-thirds of the 669 respondents with Windows 7 deployment plans cite the operating system's new features as the primary driver or a contributing factor to migration. Yet, key Windows 7 features, including DirectAccess, BranchCache, improved search, power management and better offline folder access, depend on 2008 R2 server functionality.

    • Key Windows 7 Ready Solutions
     
    • Following a thorough assessment of its customer base on their plans for Windows 7 and Windows Server 2008 R2 adoption, Lumension has taken critical steps to ready and enable organizations to successfully migrate Lumension solutions to the new Windows platforms.
    • To that end, Lumension's support for Windows 7 and Windows Server 2008 R2 includes its Lumension® Patch & Remediation, Lumension® Security Configuration Management, Lumension® Content Wizard, Lumension® Application Control, Lumension® AntiVirus and Lumension® Device Control to help organizations manage critical risk while proactively protecting vital information.
    • Lumension plans to extend support for Lumension Patch and Remediation v6.4 and Lumension® Scan to ensure c
      '/>"/>

    Source: PRWeb
    Copyright©2009 Vocus, Inc.
    All rights reserved  

    0

    GOOD

    Page: 1 2 3 4

    Related medicine news :

    1. Lumension Security Announces General Availability of Sanctuary Endpoint Protection and Data Protection Suite to Safeguard Data and Privacy
    2. Lumension Security To Showcase Vulnerability Management Expertise With Whitehatworld.com Webcast
    3. Lumension Security Launches Interactive Office Game To Educate IT Professionals On 10 Most Common Security Risks Within The Workplace
    4. Lumension Security Debuts New Customer Testimonial Video
    5. Lumension Security Launches Podcast On Application Whitelisting: Keep The Bad Guys Out - Let The Good Guys In
    6. Lumension Security Receives Frost & Sullivan 2008 Global Market Penetration Leadership Award
    7. Lumension Security To Host Industry Webinar On Staying Ahead Of Threats
    8. Lumension Security to Host Industry Webinar on Protecting Vital Business Data
    9. Lumension Uncovers Results of Security Data Protection Survey
    10. Lumension Provides Leading e-Commerce Company Proactive Endpoint Security at a High Return
    11. Lumension Security's Audiocast Focuses on Evolving Threats and Countermeasures: Achilles Heel of Data Loss and Theft

    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    Related Image:
    Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms
    Lumension Provides Enhanced Endpoint Protection and Support for The Latest Windows Platforms
    (Date:11/25/2009)...erm survivors of testicular cancer who were treate...e side effects, including neurological side effect...t treated with chemotherapy, according to a new st...f the National Cancer Institute . , Marianne Bry... University Hospital, in Bergen, Norway, and colle...
    (Date:11/25/2009)...b, already used to fight rheumatoid arthritis, cou... , WEDNESDAY, Nov. 25 (HealthDay News) -- ...ma and rheumatoid arthritis now also shows some pr...e 1 diabetes. , The drug, rituximab (Rituxan), ...nsulin, even though the disease had destroyed some...
    (Date:11/25/2009)...NEWYORK,Nov.25/PRNewswire/-- MISSIONSkincare ®...ionforSt.Jude.AspartofGNC,sannualSt.Jude Thanksand...IONSkincare,s new SUPER-C(TM)LipBalm willbedonat...unitytomakea$1,$5or$10donationatcheckoutatoneofthe...morethan$1millionforSt.Judeduringtheir2009 Thanksa...
    (Date:11/25/2009)...rious behavior problems that can occur in children... with a treatment plan that includes medication co...nts, according to Yale University researchers and ...009 issue of the Journal of the American Academy ... conducted by the National Institute of Mental Hea...
    (Date:11/25/2009)... BioSpace.com, the premier resour...led the third edition of the BioForest™ Hotb... Englewood, CO (Vocus) November 25, 2009 -- BioS...reers and information, unveiled the third edition ...ng., , , , ,This regional campaign is a promotion...
    Breaking Medicine News(10 mins):Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:MISSION Skincare(R) Supports GNC's Efforts To Raise Money for St. Jude Children's Research Hospital(R) 2Health News:Parent training key to improved treatment of behavior problems in children with autism 2Health News:BioSpace Showcases Leading Life-Science Companies in the Northwest 2
    ...ime Emmy,nominated actress Colleen Zenk Pinter, be... on CBS,s As the World Turns, has teamed up with t...r battle against oral cancer, and,raise public awa...030 ), Zenk Pinter,s first stop was CBS,s The Ea...
    ...Inc.,(CTI) (Nasdaq: CTIC ; MTAX) today announced ...imately $6.5 million of its 7% Convertible,Preferr...several,institutional investors, including certain...r share of Series D,convertible preferred stock. T...
    ...nsylvania Public,Utility Commission (PUC) approved...e case., The settlement, which was reached among ...he Office of Consumer Advocate, Office of Small,Bu...charge that customers have already been paying rel...
    ...tionally, clinicians have relied on information pr...ts as the primary means of assessing patients symp...s consequences could arise if important symptoms g...C) finds that even the sickest cancer patients are...
    ...izing their Animals and Homes, SACRAMENTO, Calif....are enough to shelter them from the cold. But acco...tion (CVMA), pets can be extremely,vulnerable in t... vary in size, age, and health status, you need to...
    ...as,treating in the Yale University-affiliated comm...Garth Graham thought he could almost be looking in... age, and lived near,Graham,s own home in New Have... and losing weight for no apparent reason. When Gr...
    Other Medicine News:Health News:Actress Colleen Zenk Pinter Partners with the Oral Cancer Foundation to Raise Public Awareness 2Health News:Actress Colleen Zenk Pinter Partners with the Oral Cancer Foundation to Raise Public Awareness 3Health News:Cell Therapeutics, Inc. Announces $6.5 Million Offering 2Health News:Cell Therapeutics, Inc. Announces $6.5 Million Offering 3Health News:Pennsylvania American Water's Rate Case Approved 2Health News:Pennsylvania American Water's Rate Case Approved 3Health News:Cancer patients may benefit from reporting symptoms online in real time 2Health News:Cancer patients may benefit from reporting symptoms online in real time 3Health News:Cancer patients may benefit from reporting symptoms online in real time 4Health News:Protect Pets From Winter's Hidden Dangers 2Health News:Protect Pets From Winter's Hidden Dangers 3Health News:Take the Test, Take Control: World AIDS Day 2007 2
    (Date:11/24/2009)...,, IRVINE,Calif.,Nov.24/PRNewswire-FirstCall...llyinvasivetreatmentsforaorticdisorders,announcedt...oceedingsin,thepatentinfringementlawsuitbroughtaga...heUnitedStatesDistrictCourtinIndianapolis,Indiana....ectwhiletheUnitedStatesPatentandTrademarkOffice(US...
    (Date:11/24/2009)...,, WOODCLIFFLAKE,N.J.andNEWYORK,Nov.24/PRNew...heU.S.FoodandDrugAdministration(FDA)hasacceptedfor...mgAricept®(donepezilHClextendedrelease)tablet...se(AD).Thisnewhigherdoseformulationcontains23mgofd...thadeliverysystemthatallowsforgradualreleaseofthed...
    (Date:11/24/2009)...,, STAMFORD,Conn.,Nov.24/PRNewswire/--Zargis...E )andaspin-offfromSiemensCorporateResearch(NYSE: ...sfeaturedontheNovember24,2009episodeofCBS, TheEarl...PopularScience magazine,reviewedfivewinningproduct...,, TheEarlyShow isawidely-viewedtelevisionmorn...
    Breaking Medicine Technology:Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 2FDA Accepts Once Daily 23 mg Aricept(R) Extended Release NDA for Review 3Zargis Cardioscan(TM) Featured on The Early Show on CBS 2Zargis Cardioscan(TM) Featured on The Early Show on CBS 3Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 1Arcadia Resources Announces Webcast of its Fiscal 2009 Fourth Quarter and Year End Conference Call 48847 2Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 1Forterus Inc Treatment Centers Serving Middle Class 3B Rapid Growth Detailed in Paul Howarth Interview 48844 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 1Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 2Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 3Parents In Wisconsin Can Now Test Their Children For Lead Exposure Using Saliva 48843 4
    ...INESS WIRE)--Apr 16, 2007 - Amgen,(Nasdaq:AMGN) to...e-blind, placebo-controlled Phase 3 study evaluati...tin alfa) for the,treatment of anemia in patients ...adiotherapy ("the 103 study"). Aranesp is not,appr... These,results were presented in an oral session a...
    ...primary endpoint not met; plausibly,confounded by ...TUX,-, NEW YORK, April 16, 2007 /PRNewswire-FirstC...yers Squibb Company today,announced detailed resul... multi-center Phase III trial - comparing ERBITUX(... in patients with,metastatic colorectal cancer (mC...
    Other Medicine Technology:Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 2Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 3Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 4Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 5Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 6Aranesp Phase 3 Study in Patients with Active Cancer Not Receiving,Concurrent Chemotherapy or Radiotherapy Presented at AACR Annual,Meeting 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 2Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 3Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 4Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 5Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 6Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 7Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 8Randomized Phase III Trial Showed Erbitux Significantly Improved,Secondary Endpoints of Progression-Free Survival and Disease,Control in Metastatic Colorectal Cancer Patients 9
    Sophia Vest V-654
    Gabrielle Vest V-650
    Female Mini-VEST, Front Closure, X-Firm
    Male Support Brief
    Medicine Products: